Tag: TSX:CRDL

January 15, 2020

Cardiol Therapeutics’ Exclusive Manufacturing Partner Receives Three-Year Renewal and Amendment of its Cannabis Act License from Health Canada

Dalton Pharma Services, has received a three-year renewal and license amendment of its Cannabis Act Processing License from Health Canada.
January 14, 2020

Cannabidiol Offering a New Approach to Acute Myocarditis Treatment

CBD’s anti-inflammatory properties could make this cannabinoid a viable treatment for heart inflammation concerns.
December 18, 2019

Cardiol Therapeutics Appoints Michael J. Willner, Esq. as Business Advisor

Cardiol Therapeutics Inc. is pleased to announce that it has appointed Michael J. Willner, Esq. as Business Advisor to the...
December 12, 2019

Top Cannabis Stocks of 2019 on the TSX, TSXV and CSE

The Investing News Network offers a closer look at 2019's top Canadian cannabis stocks on the TSX, TSXV and CSE.
December 3, 2019

Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to Its Board of Directors

Cardiol Therapeutics Inc. is pleased to announce the appointment of Mr. Colin Stott to its Board of Directors, effective immediately.
November 27, 2019

Cannabis Industry Leaders Call for CBD Testing and Regulation

Diligent CBD testing and oversight could be the key to sustained industry growth and consumer health in North American cannabis.
November 25, 2019

Cardiol Therapeutics Comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency

Cardiol Therapeutics Inc. commented on Purisys, LLC's news release issued on November 21st.